证券日报网讯1月5日，永安药业（002365）在互动平台回答投资者提问时表示，截至2025年12月19日， 公司股东人数为50868户。 ...

永安药业今年以来股价涨93.23%，近5个交易日跌0.20%，近20日跌7.41%，近60日跌15.79%。 12月18日，永安药业盘中上涨2.01%，截至10:23，报15.25元/股，成交3957.30万元，换手率1.07%，总 市值44.94亿元。 资金流向方面，主力资金净流入429.45万元，大单买入732.62万元，占比18.51%，卖出303.17万元，占 比7.66%。 资料显示，潜江永安药业股份有限公司位于湖北省潜江经济开发区广泽大道2号，成立日期2001年6月18 日，上市日期2010年3月5日，公司主营业务涉及主要从事牛磺酸产品的研发、生产和销售。主营业务收 入构成为：牛磺酸64.14%，其他35.86%。 永安药业所属申万行业为：医药生物-化学制药-原料药。所属概念板块包括：宠物经济、医药电商、跨 境电商、石墨烯、证金汇金等。 责任编辑：小浪快报 今年以来永安药业已经30次登上龙虎榜，最近一次登上龙虎榜为7月21日，当日龙虎榜净买入-2.89亿 元；买入总计1.78亿元 ，占总成交额比12.43%；卖出总计4.67亿元 ，占总成交额比32.65%。 截至11月28日，永安药业股东户数5. ...

Core Viewpoint - Yong'an Pharmaceutical (002365) clarified that its main product, taurine, is used as a food additive primarily in the food and beverage industry, and that its subsidiary, Yong'an Health, offers products suitable for fatigue relief. The company and its subsidiaries do not supply related products directly to the military [1]. Group 1 - The main product of the company is taurine, which serves as a food additive [1] - Taurine is primarily applied in the food and beverage industry [1] - Yong'an Health, a subsidiary, has products aimed at individuals seeking fatigue relief [1] Group 2 - The company and its subsidiaries have not supplied related products to the military [1]

Core Viewpoint - The company, Yong'an Pharmaceutical (002365.SZ), has clarified that it does not currently develop or produce the drug Liraglutide, which has been inquired about for its potential use in weight loss and diabetes treatment [2][4]. Group 1: Company Operations - Yong'an Pharmaceutical primarily engages in three business areas: research, production, and sales of taurine products; research, production, and sales of health foods; and research, production, and sales of special dietary foods (creatine) [2][4]. - The company has not developed or produced Liraglutide products as of the latest update [2][4].

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) is primarily engaged in three business segments: the research, production, and sales of taurine products; the research, production, and sales of health foods; and the research, production, and sales of special dietary foods (creatine) [1] Business Segments - The company focuses on the development, production, and sales of taurine products [1] - The company also engages in the research, production, and sales of health foods [1] - Additionally, the company is involved in the research, production, and sales of special dietary foods, specifically creatine [1] - Currently, the company has not commenced the production or research of limonamide products [1]

格隆汇12月2日丨永安药业(002365.SZ)在投资者互动平台表示，公司主营产品牛磺酸作为食品添加剂， 主要应用于食品、饮料行业，子公司永安康健自有品牌相关产品适合抗疲劳的人群，目前公司及子公司 均未直接向军方供应相关产品。 ...

证券日报网讯12月1日，永安药业（002365）在互动平台回答投资者提问时表示，截至2025年11月20 日，公司股东人数为53994户。 ...

（文章来源：证券日报） 证券日报网讯永安药业11月24日在互动平台回答投资者提问时表示，子公司永安康健易加能自有品牌产 品线下渠道正按计划稳步推进中。永安康健对线上和线下渠道实行了差异化的产品战略，线上主推"易 加能"自有品牌产品，线下则主推"牛番"自有品牌产品，目前"牛番"自有品牌产品已入驻云南健之佳连 锁药店。 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-67 潜江永安药业股份有限公司 关于购买理财产品的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日、2025 年 6 月 24 日分别召开了第七届董事会第六次临时会议及 2024 年年度股东会，审 议通过了《关于使用自有资金进行委托理财的议案》，同意公司及子公司总计使 用最高额度不超过（含）人民币 7.5 亿元的自有资金进行委托理财。上述额度 可滚动使用，有效期自股东会审议通过之日起不超过 12 个月，并授权公司管理 层具体实施相关事宜。公司根据上述决议，择机购买了相关理财产品，现将有关 情况公告如下： 一、理财产品的主要情况 （一）2025 年 11 月 17 日，公司出资 3000 万元，向中国中金财富证券有限 公司（以下简称"中金财富"）购买理财产品，具体情况如下： 3、预计到期年化收益率：2.3%+超额收益 4、产品收益起始日：2025 年 11 月 19 日 5、产品到期日：90 个自然日后每个开放日 ...

Core Viewpoint - The company announced the absorption merger of its associate company Huanggang Daily Chemical by its wholly-owned subsidiary Tianan Daily Chemical, which will lead to a change in investment targets and related transactions [1][4][5]. Group 1: Merger Details - The merger will not involve cash payments, and shareholders of Huanggang Daily Chemical will exchange their shares for equity in Tianan Daily Chemical on a pro-rata basis [2][5]. - After the merger, Huanggang Daily Chemical will be dissolved, and all its assets, liabilities, and equity will be inherited by Tianan Daily Chemical [5][10]. - The company's previous investment of 30 million yuan in Huanggang Daily Chemical will convert into a direct investment in Tianan Daily Chemical, maintaining a shareholding ratio of 6.5217% [2][5]. Group 2: Board Meeting and Approval - The board meeting to discuss the merger was held on November 11, 2025, with all seven directors participating, and the proposal was approved with five votes in favor and two abstentions [1][6]. - The independent directors had previously reviewed and approved the proposal before it was submitted to the board [3][6]. Group 3: Purpose and Impact - The merger aims to optimize the management structure of the associate company, reduce management costs, and improve decision-making efficiency, aligning with the company's overall development strategy [13]. - The financial statements of Tianan Daily Chemical will not be included in the company's consolidated financial statements post-merger, indicating no significant impact on the company's financial status or overall business development [13]. Group 4: Related Transactions - From January to October 2025, the total amount of related transactions between the company and its associated entities was approximately 28.19 million yuan, with 24.52 million yuan specifically involving Tianan Daily Chemical and Huanggang Daily Chemical [13].